ESR1 and breast carcinoma: ddPCR and next-generation sequencing have been utilized by multiple groups to detect ESR1 hotspot mutations in patients with advanced breast cancer (108) in an appreciable frequency (109–111), and higher in the metastatic setting as compared to micrometastatic disease (109, 112, 113).